David Karpf

9.8k total citations · 4 hit papers
38 papers, 7.6k citations indexed

About

David Karpf is a scholar working on Oncology, Orthopedics and Sports Medicine and Surgery. According to data from OpenAlex, David Karpf has authored 38 papers receiving a total of 7.6k indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 13 papers in Orthopedics and Sports Medicine and 12 papers in Surgery. Recurrent topics in David Karpf's work include Bone health and treatments (13 papers), Bone health and osteoporosis research (13 papers) and Bone and Joint Diseases (8 papers). David Karpf is often cited by papers focused on Bone health and treatments (13 papers), Bone health and osteoporosis research (13 papers) and Bone and Joint Diseases (8 papers). David Karpf collaborates with scholars based in United States, New Zealand and Russia. David Karpf's co-authors include Dennis M. Black, Steven R. Cummings, Kristine E. Ensrud, Harry K. Genant, Michael C. Nevitt, Jane A. Cauley, Desmond Thompson, Sara A. Quandt, Douglas C. Bauer and Susan M. Ott and has published in prestigious journals such as New England Journal of Medicine, The Lancet and JAMA.

In The Last Decade

David Karpf

37 papers receiving 7.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures

1996 2.9k citations Dennis M. Black, Steven R. Cummings et al. The Lancet profile →
Effect of Oral Alendronate on Bone Mineral Density and the Incidence of Fractures in Postmenopausal Osteoporosis

1995 1.8k citations Uri Liberman, Stuart Weiss et al. profile →
Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs

2002 578 citations Steven R. Cummings, David Karpf et al. The American Journal of Medicine profile →
Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment.

1994 572 citations David Karpf et al. The Journal of Clinical Endocrinology & Metabolism profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
David Karpf United States	24	5.8k	4.2k	2.5k	1.7k	761	38	7.6k
Silvano Adami Italy	46	4.9k 0.8×	4.1k 1.0×	2.9k 1.1×	1.3k 0.7×	864 1.1×	142	8.5k
Arthur C. Santora United States	38	8.4k 1.5×	6.2k 1.5×	3.3k 1.3×	2.1k 1.3×	723 1.0×	93	10.4k
S. Adámi Italy	46	4.8k 0.8×	3.6k 0.9×	2.0k 0.8×	1.1k 0.7×	583 0.8×	165	7.4k
Jean‐Jacques Body Belgium	50	2.9k 0.5×	6.1k 1.4×	2.0k 0.8×	1.7k 1.0×	552 0.7×	242	9.0k
Arkadi Chines United States	43	4.5k 0.8×	3.5k 0.8×	2.1k 0.9×	614 0.4×	1.5k 2.0×	102	6.5k
Bruce Mitlak United States	40	6.9k 1.2×	5.5k 1.3×	4.1k 1.6×	2.0k 1.2×	2.2k 2.9×	97	11.1k
Jorma Salmi Finland	27	2.5k 0.4×	2.1k 0.5×	1.7k 0.7×	1.5k 0.9×	712 0.9×	55	5.6k
Antonio Lombardi United States	20	4.0k 0.7×	3.5k 0.8×	1.6k 0.6×	810 0.5×	358 0.5×	36	5.1k
Suzanne M. Jan de Beur United States	25	2.6k 0.4×	1.7k 0.4×	1.5k 0.6×	1.4k 0.8×	1.1k 1.4×	52	5.7k
Ouhong Wang United States	10	3.1k 0.5×	2.5k 0.6×	1.9k 0.8×	802 0.5×	332 0.4×	14	4.4k

Countries citing papers authored by David Karpf

Since Specialization

Citations

This map shows the geographic impact of David Karpf's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Karpf with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Karpf more than expected).

Fields of papers citing papers by David Karpf

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Karpf. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Karpf. The network helps show where David Karpf may publish in the future.

Co-authorship network of co-authors of David Karpf

This figure shows the co-authorship network connecting the top 25 collaborators of David Karpf. A scholar is included among the top collaborators of David Karpf based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Karpf. David Karpf is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Khan, Aliya, Lars Rejnmark, Mishaela R. Rubin, et al.. (2021). PaTH Forward: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of TransCon PTH in Adult Hypoparathyroidism. The Journal of Clinical Endocrinology & Metabolism. 107(1). e372–e385. 28 indexed citations

Brod, Meryl, et al.. (2020). Living with hypoparathyroidism: development of the Hypoparathyroidism Patient Experience Scale-Impact (HPES-Impact). Quality of Life Research. 30(1). 277–291. 12 indexed citations

Karpf, David, et al.. (2020). A Randomized Double-Blind Placebo-Controlled First-In-Human Phase 1 Trial of TransCon PTH in Healthy Adults. Journal of Bone and Mineral Research. 35(8). 1430–1440. 31 indexed citations

Karpf, David, Chelsea Catsburg, & Alden Smith. (2020). Prevalence of hypoparathyroidism in the EU: A systematic review and meta-analysis. Endocrine Abstracts.

Maniatis, Aristides K, Paul Saenger, Gail J. Mick, et al.. (2020). OR10-05 Phase 3 FliGHt Trial: Experience of Switching from Daily Growth Hormone Therapy to Once-Weekly TransCon HGH in Children with Growth Hormone Deficiency. Journal of the Endocrine Society. 4(Supplement_1). 3 indexed citations

Brod, Meryl, et al.. (2019). Assessing the Patient Experience of Hypoparathyroidism Symptoms: Development of the Hypoparathyroidism Patient Experience Scale-Symptom (HPES-Symptom). Patient. 13(2). 151–162. 26 indexed citations

Holten-Andersen, Lars, Susanne Pihl, C.E. Rasmussen, et al.. (2019). Design and Preclinical Development of TransCon PTH, an Investigational Sustained-Release PTH Replacement Therapy for Hypoparathyroidism. Journal of Bone and Mineral Research. 34(11). 2075–2086. 33 indexed citations

Thornton, Paul, Paul L. Hofman, Aristides K Maniatis, et al.. (2019). OR17-4 Transcon Growth Hormone In The Treatment Of Pediatric Growth Hormone Deficiency: Results Of The Phase 3 Height Trial. Journal of the Endocrine Society. 3(Supplement_1). 7 indexed citations

Karpf, David. (2018). The Many Faces of Resistance Media. Oxford University Press eBooks. 2 indexed citations

10.

Choi, Yun‐Jung, Brian K. Roberts, Xueyan Wang, et al.. (2011). Effects of the PPAR-δ agonist MBX-8025 on atherogenic dyslipidemia. Atherosclerosis. 220(2). 470–476. 59 indexed citations

11.

Bays, Harold, Sherwyn Schwartz, Thomas Littlejohn, et al.. (2011). MBX-8025, A Novel Peroxisome Proliferator Receptor-δ Agonist: Lipid and Other Metabolic Effects in Dyslipidemic Overweight Patients Treated with and without Atorvastatin. The Journal of Clinical Endocrinology & Metabolism. 96(9). 2889–2897. 133 indexed citations

12.

Liu, Hau, Kaleb Michaud, Smita Nayak, et al.. (2006). The Cost-effectiveness of Therapy With Teriparatide and Alendronate in Women With Severe Osteoporosis. Archives of Internal Medicine. 166(11). 1209–1209. 64 indexed citations

13.

Cummings, Steven R., David Karpf, Fran Harris, et al.. (2002). Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. The American Journal of Medicine. 112(4). 281–289. 578 indexed citations breakdown →

14.

Chen, Yu, Theodore L. DeWeese, Jeanette Dilley, et al.. (2001). CV706, a prostate cancer-specific adenovirus variant, in combination with radiotherapy produces synergistic antitumor efficacy without increasing toxicity.. PubMed. 61(14). 5453–60. 129 indexed citations

15.

Liberman, Uri, Stuart Weiss, H. W. Minne, et al.. (1996). Effect of Oral Alendronate on Bone Mineral Density and the Incidence of Fractures in Postmenopausal Osteoporosis. Obstetrical & Gynecological Survey. 51(4). 238–241. 62 indexed citations

16.

Black, Dennis M., Steven R. Cummings, David Karpf, et al.. (1996). Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. The Lancet. 348(9041). 1535–1541. 2935 indexed citations breakdown →

17.

Karpf, David, et al.. (1991). Features of the renal parathyroid hormone-parathyroid hormone-related protein receptor derived from structural studies of receptor fragments. Journal of Bone and Mineral Research. 6(2). 173–182. 13 indexed citations

18.

Karpf, David, Claude D. Arnaud, Thomas Bambino, et al.. (1988). Structural Properties of the Renal Parathyroid Hormone Receptor: Hydrodynamic Analysis and Protease Sensitivity*. Endocrinology. 123(6). 2611–2620. 17 indexed citations

19.

Karpf, David, Claude D. Arnaud, Kathy King, et al.. (1987). The canine renal parathyroid hormone receptor is a glycoprotein: characterization and partial purification. Biochemistry. 26(24). 7825–7833. 25 indexed citations

20.

Karpf, David, et al.. (1986). Current concepts in acromegaly: etiology, diagnosis, and treatment.. PubMed. 12(1). 22–30. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact